Equillium/$EQ
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Equillium
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Ticker
$EQ
Sector
Primary listing
Employees
35
Headquarters
Website
Equillium Metrics
BasicAdvanced
$62M
-
-$0.57
1.88
-
Price and volume
Market cap
$62M
Beta
1.88
52-week high
$2.35
52-week low
$0.27
Average daily volume
504K
Financial strength
Current ratio
10.853
Quick ratio
10.744
Long term debt to equity
1.529
Total debt to equity
2.408
Profitability
EBITDA (TTM)
-24.242
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-555.94%
Operating margin (TTM)
-554.87%
Effective tax rate (TTM)
-1.50%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-44.17%
Return on equity (TTM)
-90.24%
Valuation
Price to revenue (TTM)
10.01
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-1.918
Free cash flow yield (TTM)
-52.13%
Free cash flow per share (TTM)
-0.532
Growth
Revenue change (TTM)
-90.43%
Earnings per share change (TTM)
337.48%
3-year earnings per share growth (CAGR)
-37.41%
Equillium News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Equillium stock?
Equillium (EQ) has a market cap of $62M as of November 27, 2025.
What is the P/E ratio for Equillium stock?
The price to earnings (P/E) ratio for Equillium (EQ) stock is 0 as of November 27, 2025.
Does Equillium stock pay dividends?
No, Equillium (EQ) stock does not pay dividends to its shareholders as of November 27, 2025.
When is the next Equillium dividend payment date?
Equillium (EQ) stock does not pay dividends to its shareholders.
What is the beta indicator for Equillium?
Equillium (EQ) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.